A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma

Phase 2

Completed

Conditions: Advanced Renal Cell Carcinoma

Interventions: Drug: AMG 102 at 20 mg/kg
Drug: AMG 102 at 10 mg/kg

Registration Number: NCT00422019

Lead Sponsor: Amgen

Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of AMG 102 in patients with Advanced Renal Cancer.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 61

Inclusion Criteria

documented histologically confirmed advanced or metastatic renal cell carcinoma with the primary tumor in place or following nephrectomy
measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques (CT or MRI) or ≥ 10 mm by spiral CT scan
no more than 3 relapses (or prior systemic treatments)
unable to receive or failed prior therapy with vascular endothelial growth factor (VEGF) binding agents or VEGF receptor tyrosine kinase inhibitors or other multi-kinase inhibitors
tissue blocks or tissue sections from initial or upon diagnosis of advanced metastatic disease are available for submission to the central laboratory within approximately 4 weeks after enrollment or approval is granted by the sponsor (upon receipt of justification why the sample is not available)
age ≥ 18 years
ECOG performance status of 0-2
hemoglobin concentration ≥ 9 g/dL
absolute neutrophil count ≥ 1.5 x 10(9th)/L
corrected serum calcium ≤ 10 mg/dL
either serum creatinine < 2.0 x upper limit of normal OR creatinine clearance > 40 mL/min
alanine aminotransferase ≤ 2.5 times upper limit of normal or < 5.0 x ULN if the subject has documented liver metastasis or primary hepatic neoplasm
serum total bilirubin ≤ 2.5 times upper limit of normal
before any study-specific procedure, the appropriate written informed consent must be obtained

Exclusion Criteria

active brain metastases; brain metastases allowed provided they have been treated with surgery and/or radiation therapy and show no evidence of progression on cerebral CT or MRI scan 2 months following surgery and/or radiation therapy
concurrent severe and/or uncontrolled medical disease (e.g., uncontrolled diabetes, congestive cardiac failure, myocardial infarction within 6 months before enrollment) that could compromise participation in the study
documented history of human immunodeficiency virus infection
documented history of viral chronic hepatitis
received biologic, small molecule, immunotherapy, chemotherapy, radiotherapy or other agents to treat renal cancer within 28 days before enrollment
treated previously with c-Met or HGF targeted therapy
concurrent or prior (within 7 days before enrollment) anticoagulation therapy, except:
- Use of low-dose warfarin (< 2 mg/day) for prophylaxis against central venous catheter thrombosis or
- Use of low molecular weight heparins (LMWH, e.g., enoxaparin sodium [Lovenox] and unfractionated heparin for prophylaxis against central venous catheter thrombosis is allowed
concurrent use of hormones or other chemotherapeutic agents except for steroids given for adrenal failure and hormones administered for non-disease-related conditions (eg, insulin for diabetes); except for non-cancer reasons
concurrent palliative or therapeutic radiation therapy
currently enrolled in or has not yet completed at least 30 days since ending other investigational device or therapy, or subject is receiving other investigational agent(s)
active infection requiring treatment within 1 week before enrollment
undergone major surgery within 4 weeks before enrollment or recovering from prior surgery
past or current history of another neoplasm, except for curatively treated non-melanoma skin cancer, carcinoma in situ of the cervix and other primary solid cancer with no known active disease present and no curative treatment administered for the last 3 years
known allergy or sensitivity to any of the excipients in the investigational product to be administered
pregnant or is breast feeding
not consenting to use adequate contraceptive precautions during the course of the study and for 6 months after the last administration of investigational product:
- female subjects who are not post-menopausal (no menstrual period for a minimum of 12 months at study entry) or documented surgically sterile will not be bound to this exclusion
previously treated with AMG 102
previously enrolled into this study
will not be available for follow-up assessments
has other disorders that compromises the ability of the subject to give written informed consent and/or comply with study procedures
unable to begin protocol specified treatment within 3 days after enrollment

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AMG 102 at 20 mg/kg Dose Level	AMG 102 at 20 mg/kg	Up to 40 subjects will be treated at 20 mg/kg of AMG 102 Q2W (every 2 weeks) depending upon the stage of the study and number of responses observed.
AMG 102 at 10 mg/kg Dose Level	AMG 102 at 10 mg/kg	Up to 40 subjects will be dosed at 10mg/kg of AMG 102 Q2W (every two weeks) based upon the stage of the study and number of responses observed.

Primary Outcome Measures

Name	Time	Method
To assess the objective response rate in subjects with advanced renal cell carcinoma receiving AMG 102 treatment	9 weeks from first dose of AMG 102

Secondary Outcome Measures

Name	Time	Method
To estimate the overall survival and progression free survival rates in this population	8 week intervals
To assess the duration of response and time to response in this population	treatment period
To assess the pharmacokinetics of AMG 102 in subjects with advanced renal cell carcinoma	Weeks 1, 5, and 9
To assess the safety profile of AMG 102 in subjects with advanced renal cell carcinoma	entire study